Nevertheless, we acknowledge that while anti-tumor effects of C4 serve as a proof of principle for the efficiency of pharmacological interference with IGF2BP2 activity for cancer treatment, C4 is not likely to serve as an actual drug for cancer therapy. The gene discussed is C4A; the disease is neoplasm.